Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
anavex life sciences股票交易上涨，因公司宣布来自IIb/III期研究的新数据显示，一日一次口服的Blarcamesine通过上游SIGMAR1激活展示了预设的临床疗效。
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
anavex life sciences股份上涨，在公司宣布来自IIb/III期研究的新数据后显示，Blarcamesine，每日一次口服，通过上游SIGMAR1激活呈现预设临床疗效。
资讯热榜
更新时间